Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
46.25
-1.28 (-2.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
28
29
Next >
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
July 01, 2022
From
The Schall Law Firm
Via
Business Wire
How Is The Market Feeling About Sanofi?
July 01, 2022
Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold
June 30, 2022
The company was testing the drug in multiple sclerosis and myasthenia gravis.
Via
Investor's Business Daily
Why Sanofi Shares Are Falling Today
June 30, 2022
Via
Benzinga
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
May 31, 2022
The U.S.
Via
Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
June 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'
June 29, 2022
The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,...
Via
Benzinga
Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients
June 29, 2022
Via
Benzinga
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes
June 24, 2022
The companies' shot was more than 93% effective in previously infected people.
Via
Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
June 24, 2022
Reuters
Via
Benzinga
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
June 24, 2022
Via
Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
June 23, 2022
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge...
Via
Benzinga
Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry
June 21, 2022
Companies like Tilray Inc. (NASDAQ: TLRY) and Cara Therapeutics Inc.
Via
Benzinga
Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes
June 17, 2022
Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session.
Via
InvestorPlace
Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors
June 14, 2022
Pharmaceutical startup CLVS stock is climbing 25% higher today on rumors that the cancer drug maker has become a takeover target.
Via
InvestorPlace
Morning Brief: Top Financial Stories Dominating on Monday, June 13
June 13, 2022
CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why
Via
Benzinga
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
June 13, 2022
Via
Benzinga
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit
June 10, 2022
The conversation around obesity is changing. Two diabetes drug makers are at the forefront.
Via
Investor's Business Daily
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
June 09, 2022
Via
AB Newswire
Exposures
Product Safety
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
June 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
June 07, 2022
The U.S.
Via
Benzinga
CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment
June 07, 2022
Key Takeaways: CStone brought four products to market last year, and its losses have surged due to growing R&D and sales spending Appointment of chairman with close ties...
Via
Benzinga
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
June 06, 2022
Via
AB Newswire
Exposures
Product Safety
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
June 05, 2022
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Via
Benzinga
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer
June 02, 2022
Regeneron secured the global rights to Sanofi-partnered Libtayo.
Via
Investor's Business Daily
3 Biotech Stocks to Buy Before They Boom
June 01, 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.
Via
InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
May 31, 2022
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood...
Via
FinancialNewsMedia
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.